Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), through its specialty pharmaceuticals subsidiary, TEAMM Pharmaceuticals, Inc., has developed MD Turbo. It is the first and only available product that transforms many of the most commonly prescribed metered dose inhalers (MDIs) into breath-activated, dose-counting inhalers. MD Turbo will be available at pharmacies in May of this year.
Gary Cantrell, TEAMM Executive Vice President of Sales and Marketing said, "MDIs are most often used as rescue medications during acute attacks. Improper dosing and other misuses can lead to negative outcomes, such as the exacerbation of symptoms and even hospitalization. But with MD Turbo physicians will be able to prescribe their drug of choice in combination with an easy to use, handheld, breath-activated device to overcome the delivery challenges often facing their patients."
"MDIs have been around for about 50 years. But MD Turbo is the first companion product to solve two of the biggest challenges facing MDI users: coordination of inhaler actuation with patient's breath, and the accounting of how much medication is left in the inhaler. We are all very excited about introducing a new product to the market that can improve the quality of care," said an excited Gil Mott, President and Chief Executive Officer of Respirics Inc.
More than 40 million MDIs are prescribed each year in the United States alone.
So it would be a lease of fresh air for many asthma patients.